Welcome to our dedicated page for VAXART news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on VAXART stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart (OTCQX: VXRT) announced that the European Patent Office has granted European Patent No. 3791859, effective August 26, 2026, covering its oral recombinant norovirus vaccine candidate.
The patent extends protection of Vaxart’s norovirus program and room‑temperature stable, needle‑free pill technology through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom, with validation planned in additional key territories.
Vaxart (OTCQX: VXRT) reported second quarter 2026 topline safety data from the 400-participant sentinel cohort of its Phase 2b COVID-19 oral pill vaccine trial, conducted against an approved mRNA comparator. No vaccine-related serious adverse events or sustained Grade 3+ adverse events were observed in either arm. The most common events for the pill were malaise/fatigue and headache, while the mRNA arm showed injection site pain/tenderness, malaise/fatigue, headache, and myalgia.
According to Vaxart, topline efficacy and safety data from the full Phase 2b study (about 5,400 participants) are expected in the first half of 2027. A BARDA contract modification increased authorized funding for the study to $344.8 million. Q2 2026 revenue was $27.2 million, primarily from government contracts and $2.9 million from a Dynavax agreement. R&D expense fell to $33.7 million, G&A rose to $6.6 million, and net loss narrowed to $13.5 million (or $0.06 per share). Cash, cash equivalents, and investments totaled $64.0 million at June 30, 2026, with an anticipated cash runway into the second quarter of 2027.
Vaxart (OTCQX: VXRT) will host a virtual stockholder fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular FAQ-focused series for investors.
The company plans to report second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 6, 2026. The live webcast and replay will be available via www.vaxart.com, and investors can submit written questions in advance by email to IR@vaxart.com or through the webcast portal. Vaxart is a clinical-stage biotechnology company developing oral pill vaccines for coronavirus, norovirus, influenza and a therapeutic HPV program using its proprietary recombinant vaccine delivery platform.
Vaxart (OTCQX: VXRT) announced that its management team will participate in the BTIG Biotechnology Conference 2026, held virtually on Tuesday, July 28, 2026, in a 1x1 meetings format.
The company develops oral recombinant pill vaccines targeting coronavirus, norovirus, influenza and a therapeutic HPV vaccine, using a proprietary non‑refrigerated delivery platform and has filed broad domestic and international patent applications.
Vaxart (Nasdaq: VXRT) reported voting results from its July 16, 2026 Annual Meeting of Stockholders, held in a virtual-only format. Stockholders approved two proposals recommended by the Board: the election of six director nominees to serve until the 2027 Annual Meeting and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm.
Stockholders did not approve, on a non-binding advisory basis, the compensation of Vaxart’s named executive officers (“say-on-pay”) as disclosed in the proxy statement. According to Vaxart, final voting results will be filed with the SEC on a Form 8-K. The company also reiterated its focus on developing oral recombinant pill vaccines using its proprietary delivery platform.
Vaxart (OTCQX: VXRT) reported topline 12‑month safety data from the 400‑participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID‑19 vaccine versus an approved mRNA comparator targeting XBB.
No vaccine‑related SAEs or sustained Grade 3+ AEs occurred in either arm. Topline data from the full trial, including ~5,000 participants in the main KP.2 cohort, are anticipated in 2027. Vaxart’s Project NextGen award is valued at up to $344.8 million.
Vaxart (OTCQX: VXRT) reached a cooperation agreement with a stockholder group, resolving the proxy contest tied to its 2026 Annual Meeting. The stockholder group will withdraw three director nominations.
Vaxart will search within 90 days post-meeting for a mutually agreed independent director and will form new Stockholder Engagement and Clinical and Regulatory Affairs Board committees, refresh committee chairs, and adopt director stock ownership and resignation policies.
Summary not available.
Vaxart (OTCQX: VXRT) updated its BARDA funding award for the Phase 2b COVID-19 oral pill vaccine trial. Total available trial funding is now about $345 million, down roughly $116 million after an earlier BARDA partial termination and ~50% participant reduction.
The latest modification releases about $29 million to complete the trial and exploratory analyses. Vaxart plans to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.
Vaxart (OTCQX: VXRT) released a shareholder letter from new independent directors James Breitmeyer and Kevin Finney ahead of the July 16, 2026 Annual Meeting.
The directors urge stockholders to vote “FOR” all six Vaxart nominees on the WHITE proxy card, emphasizing board continuity, oversight of Phase 2b COVID-19 work, the Dynavax funding partnership, and responses to BARDA stop-work orders amid a dissident group’s attempt to replace half the board.